1Brouet A, Sonveaux P, Dessy C, et al. Hsp90 and caveolin are key targets for the proangiogenic nitic oxide-mediated effects of statins. Circ Res, 2001,89:866-873.
2Su SF, Hsaio CL, Chu CW, et al. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am J Cardiol, 2000, 86:514-518.
3Lee TM, Chou TF, Tsai CH. Association of pravastatin and left ventricular mass in hyper- cholesterolemia patients: role of 8-Iso-Prostaglandin F2α formation. J Cardiovasc Pharmacol, 2002, 40:868-874.
4Luo JD, Zhang WW, Zhang GP, et al. Effects of simvastatin on left ventricular hypertrophy and function in rats with aortic stenosis. Acta Pharmacol Sin, 1999, 20: 345-348.
5Aikawa R, Komuro I, Yamazaki T, et al. Oxidative stress activates extracellular signal-regulated kinase through Src and Ras in culured cardiac myocytes of neonatal rats. J Clin Invest, 1997, 100:1813-1821.
6Bauersachs J, Galuppo P, Fraccarollo D, et al. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation, 2001,104
7Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344:1383-1389.
8Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995, 333:1301-1307.
9Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J, 2003, 24:225-248.
10Indolfi C, Di Lorenzo E, Perrino C, et al. Hydroxy-methylglutaryl-conezyme A reductase inhibitior simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation, 2002, 106:2118-2124.
9Arnlov J,Evans JC,Meigs JB. Low-Grade albuminuria and incidence of cardiovcascular disease events in northypertensive and nondiabetic individuals:the Franmingham Heart Study[J].Circulation,2005.969-975.
10Wassmann S,Laufs U,Bumer AT. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species[J].Hypertension,2001,(06):1450-1457.
